Erythropoietin in the treatment of cancer

Onkologie

Volumn 28, Issue 4, 2005, Pages 181-182

  Henke, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT;

ANEMIA; CANCER; CANCER CONTROL; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; ERYTHROPOIESIS; GENETIC TRANSCRIPTION; HUMAN; QUALITY OF LIFE; METHODOLOGY; MORTALITY; NEOPLASM; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ERYTHROPOIETIN; HUMANS; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20844433536     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084038     Document Type: Editorial

References (5)

1. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
2. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
3. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
4. Vaupel P, Dunst J, Engert A, Fandrey J, Feyer P, Freund M, Jelkmann W: Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. Onkologie 2005;28: DOI: 10.1159/000084033.
5. Dunst J: Management of anemia in patients undergoing curative radiotherapyerythropoietin, transfusions, or better nothing? Strahlenther Onkol 2004;180:671-681.